Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PDC-1421 Capsule
PDC-1421 · 5 trials · 2 indications
The ADHD-RS-IV with Adult Prompts is an 18-item scale based on the DSM-IV-TR criteria for ADHD that provides a rating of the severity of symptoms. The adult prompts serve as a guide to explore more fully the extent and severity of ADHD symptoms and create a framework to ascertain impairment. The odd-numbered 9 items assess inattentive symptoms and the even-numbered 9 items assess hyperactive-impulsive symptoms. Scoring is based on a 4-point, yielding a possible total score of 0-54. Likert-type severity scale: 0 = Never or Rarely, 1 = Sometimes, 2 = Often, 3 = Very Often. Clinicians should score the highest score that is generated for the prompts for each item. The ADHD-RS-IV was assessed from Visit 1 to Visit 7 by the investigator.
The MADRS is a 10-item checklist of depressive symptoms. Each Item is rated on a scale of 0-6, with anchors at 2-point intervals; higher scores indicating more severity (i.e., ranging from 0 \[no sadness\] to 6 extremely despondent\]). The total MADRS score was calculated by summing the ratings of all items. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity).
Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 1, 2, 3, 4, and 5 in patients taking 1 or 2 PDC-1421 capsules. The MADRS is a 10-item checklist including 1) depression \[apparent\]; 2) depression \[reported\]; 3) loss of interest; 4) suicidal ideation; 5) tension; 6) reduced appetite; 7) insomnia; 8) difficulty in activities; 9) concentration; and 10) pessimism. The MADRS is administered by a trained interviewer. Each item is rated on a scale of 0-6, with anchors at 2-point intervals; higher scores indicating more severity (i.e., ranging from 0 \[no sadness\] to 6 \[extremely despondent\]). The total score is used to define treatment response (≥50% reduction from baseline) and partial response (20-49% reduction from baseline). Remission is defined as a score of \< 10. The following are used as an interpretation of scores: 0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression \>34 - severe depression
Physical examination, including skin, head, neck, eyes, ears, nose, throat, heart, lungs, abdomen (liver and spleen), neurological examination, lymph node and extremities, is measured at each visit from screening to follow-up.
Electrocardiograph (ECG) is measured at each visit. At visit 2, subjects were measured at 1,2, 4, 8, 12 and 24 hours after drug administration.
Vital sign, including heart rate, blood pressure and body temperature, are measured at each visit and at 1,2,3,4,8,12 and 24 hours after drug administration.
Laboratory tests are composed of hematology and blood chemistry and measured at each visit. Hematology are composed of RBC, WBC, platelets, hematocrit, hemoglobin, prothrombin time (PT) and partial thromboplastin time (aPTT). Blood chemistry are composed of AST, ALT, LDH, total bilirubin, BUN, serum creatinine, free thyroxine (FT4), TSH, sodium, calcium, potassium, glucose, LDL, HDL, cholesterol and HbA1c.
C-SSRS is composed of suicidal ideation, intensity of ideation and suicidal behavior and measured at each visit.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Two placebo capsules thrice daily for 56 days (8 weeks). |
| Low-dose | EXPERIMENTAL | One placebo capsule and 1 PDC-1421 Capsule, thrice daily for 56 days (8 weeks). |
| High-dose | EXPERIMENTAL | Two PDC-1421 Capsules thrice daily for 56 days (8 weeks). |
| Low dose + Low dose | EXPERIMENTAL | 1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 + 28 days |
| Low dose + High dose | EXPERIMENTAL | 1 PDC-1421 Capsule for 28 days + 2 PDC-1421 Capsules for 28 days, trice daily, p.o. after meals |
| Part I: 1 PDC-1421 Capsule | EXPERIMENTAL | 1 PDC-1421 Capsule TID, p.o. after meal for 28 days |
| Part I: 2 PDC-1421 Capsule | EXPERIMENTAL | 2 PDC-1421 Capsule TID, p.o. after meal for 28 days |
| Part II: 2 PDC-1421 Capsule | EXPERIMENTAL | 2 PDC-1421 Capsule TID, p.o. after meal for 42 days |
| Part II: 1 PDC-1421 Capsule plus 1 placebo | EXPERIMENTAL | 1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days |
| Part II: 2 placebo | PLACEBO_COMPARATOR | 2 placebo TID, p.o. after meal for 42 days |
| 1 PDC-1421 Capsule | EXPERIMENTAL | 1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days |
| 2 PDC-1421 Capsules | EXPERIMENTAL | 2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days |
| PDC-1421 | EXPERIMENTAL | Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days. |
| Placebo control | PLACEBO_COMPARATOR | Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days. |
| Name | Type | Description |
|---|---|---|
| PDC-1421 Capsule | DRUG | PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as the active ingredient. |
| Placebo | DRUG | The placebo contained corn starch. |
| PDC-1421 | DRUG | - |
Inclusion Criteria: 1. Aged 18-70 years 2. Female subjects of child-bearing potential must test negative to pregnancy and use appropriate birth control method from the beginning of study to the 15 days later after ending of study 3. Subjects must be able to understand and willing to sign informed c...
PDC-1421 is an investigational small molecule developed by ABVC BioPharma, Inc. for psychiatric conditions. It is being studied in Attention-Deficit Hyperactivity Disorder (ADHD) and Major Depressive Disorder. PDC-1421 is a Phase 2 clinical-stage candidate and is also referred to as PDC-1421 Capsule.
PDC-1421 is being developed for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults. Clinical trials have evaluated PDC-1421 in adult patients with ADHD, including a completed Phase 2 study of 99 participants conducted in the United States and Taiwan.
PDC-1421 is being developed by ABVC BioPharma, Inc., which trades under the ticker ABVC. The company is the sponsor of the clinical program evaluating PDC-1421 in ADHD and Major Depressive Disorder.
PDC-1421 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The program includes completed Phase 2 trials in ADHD and Major Depressive Disorder, as well as a Phase 1/2 study in depression in cancer patients.
PDC-1421 has been studied in several registered trials. These include NCT05202327 and NCT02699086 in adult ADHD, NCT02395978 in Major Depressive Disorder, and NCT03833206, a Phase 1/2 study of PDC-1421 for treating depression in cancer patients. Total enrollment across these trials is 114 participants.
Yes, PDC-1421 Capsule is an alternative name for PDC-1421. The capsule formulation has been used in clinical studies, including a Phase 2 trial in patients with Major Depressive Disorder. Both names refer to the same investigational drug candidate.